CSL Behring


CSL Behring has been at the forefront of biotherapeutics research and development for more than 100 years. We trace our roots to Emil von Behring, the first Nobel Prize recipient in physiology and medicine. CSL Behring and the collective group of CSL businesses have a heritage of outstanding contributions to medicine and human health.

Throughout the years our passion and commitment to delivering on our promise to save and improve the lives of people with rare and serious diseases has remained strong. We are proud of our history, and we’re excited about the future. Our ability to innovate and deliver lifesaving products for patients with unmet medical needs around the world continues to grow in response to the demand for our products.

Today, we are one of the largest and fastest growing biotherapeutics businesses in the world with more than 16,000 employees delivering medicines to patients in over 60 countries. We offer the broadest range of quality plasma derived and recombinant therapies in the biotherapeutics industry, and have substantial markets in North America, Europe, Asia and Australia.

Our products are used around the world to treat the following conditions:

  • immune disorders;
  • autoimmune diseases
  • bleeding disorders;
  • hereditary angioedema;
  • alpha-1 antitrypsin deficiency; and
  • critical care products used in cardiac surgery, as well as to treat trauma, shock and burns, and to prevent haemolytic disease of the newborn.

 

We focus on patients

The people who trust and rely on our products come first in everything we do. We are keenly aware that our therapies are essential to their health and well-being, and we bring that sense of purpose to work every day. We are passionate about meeting the needs of patients, which begins with listening to them and their healthcare providers.

We work with patient groups, plasma donors, researchers, physicians, nurses, pharmacists and home healthcare companies to achieve better results. This includes promoting quality care, improving patient access to care, expanding educational and outreach efforts, and affecting public healthcare policy.

Recognised and respected by patient organisations worldwide

We strive to be the best at what we do, and we are proud that our pioneering work in developing therapies to treat rare and serious conditions has received recognition from patient organisations worldwide.

This includes the 2017 National Organization for Rare Disorders (NORD) Rare Impact Award for Innovation, the 2016 Breakthrough Innovator Award from Marcum and Smart CEO magazine, the 2015 National Hemophilia Foundation’s (NHF) Corporate Leadership Award, the 2012 EURORDIS (European Organization for Rare Diseases) Award, and the 2011 Corporate Award from the National Organization of Rare Disorders.

The thousands of talented employees at CSL Behring who share our vision, values and passion for saving lives are the engine that drives our superior performance.

Broadest range of therapies to treat rare diseases

CSL Behring is a global leader in immunoglobulins (Ig). Our portfolio of innovative medicines also includes a wide range of recombinant and plasma-derived products for treating bleeding disorders as well as products to treat hereditary angioedema and alpha-1 antitrypsin deficiency.

CSL Behring also manufactures critical care products that are used in cardiac surgery and organ transplantation, and to treat trauma, shock, burns and acquired bleeding. They are also used to reverse the effects of warfarin and to prevent haemolytic disease of the newborn.

World-class R&D: unlocking the promise of proteins

Innovation has been in our DNA since our beginnings and continues at the core of everything we do today. Our integrated R&D global organisation is driven by an experienced team of research experts who work collaboratively at worldwide locations. They continually explore new innovations to unlock the promise of biotherapies. Their contributions to medicine and human health have been possible because we continually grow our investment in R&D.